FMBA begins clinical trials of its coronavirus vaccine

The Federal Biomedical Agency (FMBA) has begun phase I and II clinical trials of its CORONAVIRUS drug. This was reported by the press service of the FMBA.

The study will involve 200 people aged 18 to 60 years. “In June 2021, preclinical studies of the vaccine preparation were successfully completed, as a result of which its safety, immunogenicity and protectiveness (protective potential) were proved,” the message says.

The developer of the vaccine is the St. Petersburg Research Institute of Vaccines and Serums of the Federal Medical and Biological Agency of RUSSIA.

The FMBA has promised a vaccine that protects against any mutation of covid-19 Society The
production of the vaccine should begin by the end of the year. The HEAD of the agency, Veronika Skvortsova, said in March that the vaccine would appear in 11 months.
In early June, Skvortsova said that the FMBA vaccine would protect the body against any mutation of the virus.

Now four vaccines against coronavirus have been registered in Russia: Sputnik V and Sputnik Light from the Center. N.F. Gamalei, "EpiVakKorona", developed by the Novosibirsk Center "Vector", and "KoviVak" from the Center. Chumakov.
July 19, 11:15 Moscow time Coronavirus Russia Moscow World +18764 (per day) 5.4 million Recovered 0 +24633 (per day) 5.9 million Infected 0 +719 (per day) 149.1 thousand Died +7665 ( per day) 1.3 million Recovered 0 +4007 (per day) 1.5 million Infected 0 +103 (per day) 24.5 thousand Died +274530 (per day) 125.3 million Recovered 0 +425285 (per day) ) 190.4 million Infected 0 +6648 (per day) 4.1 million Died Source: JHU,
Federal and Regional
Virus Control Headquarters Source: JHU, Federal and Regional Virus Control Headquarters Read more